Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) FCF Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed FCF Margin for 6 consecutive years, with 33.0% as the latest value for Q4 2023.

  • On a quarterly basis, FCF Margin rose 32102352.0% to 33.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 119.08%, a 70013.0% increase, with the full-year FY2023 number at 112.22%, up 713263.0% from a year prior.
  • FCF Margin was 33.0% for Q4 2023 at Denali Therapeutics, up from 7341.59% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 63.98% in Q3 2022 to a low of 321056.52% in Q4 2022.
  • A 5-year average of 29837.19% and a median of 577.01% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -32057194bps in 2022, then surged 32102352bps in 2023.
  • Denali Therapeutics' FCF Margin stood at 191.05% in 2019, then tumbled by -1334bps to 2738.71% in 2020, then surged by 82bps to 484.58% in 2021, then plummeted by -66155bps to 321056.52% in 2022, then soared by 100bps to 33.0% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's FCF Margin are 33.0% (Q4 2023), 7341.59% (Q3 2023), and 2219.16% (Q2 2023).